Actinium Pharmaceuticals, Inc.
275 Madison Avenue, 7th Floor
New York, NY 10016
October 3, 2017
VIA EDGAR
Irene Paik
Dorrie Yale
Division of Corporation Finance
Office of Healthcare & Insurance
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
| Re: | Actinium Pharmaceuticals, Inc. |
Form 10-K for the Fiscal Year Ended December 31, 2016
Filed March 16, 2017
File No. 001-36374
Dear Ms. Paik and Ms. Yale:
We are in receipt of your comment letter dated September 26, 2017 regarding the above referenced filing. As requested in your letter, we have provided responses to the questions raised by the staff. For your convenience, the comments are listed below, followed by Actinium Pharmaceuticals, Inc.’s responses:
Form 10-K for the Fiscal Year Ended December 31, 2016
Item 1. Business
Summary of Material Agreements Related to our Business, page 8
| 1. | In future filings, please expand your discussion of your material agreements to provide a description of the term and termination provisions of such agreements. If the term of the agreement coincides with the royalty term, which is connected to patent expiration, please also disclose any material patent expiration dates. If applicable, and if the royalty term is different from the term of the agreement, please also disclose the royalty term. |
RESPONSE: In future filings, where applicable, we will expand our discussion of our material agreements to provide a description of the term and termination provisions of such agreements. If the term of the agreement coincides with the royalty term, which is connected to patent expiration, we will also disclose any material patent expiration dates. If applicable, and if the royalty term is different from the term of the agreement, we will also disclose the royalty term.
Intellectual Property Portfolio, page 10
| 2. | In future filings, please revise your discussion of your patent portfolio to provide the following information for each material patent or patent family: |
| ● | Specific products, product groups and technologies to which such patents relate; | |
| ● | Type of patent protection such as composition of matter, use or process; | |
| ● | Patent expiration dates; | |
| ● | Identification of applicable jurisdictions; and | |
| ● | Contested proceedings and/or third-party claims, if any. |
RESPONSE: In future filings, where applicable, we will revise our discussion of our patent portfolio to provide the information listed above for each material patent or patent family.
Sincerely,
Actinium Pharmaceuticals, Inc.
| By: | /s/ Sandesh Seth | |
| Sandesh Seth | ||
| Chairman and Chief Executive Officer |